Endocannabinoid Deficiency is becoming recognized as a condition worth treating with supplemental phytocannabinoids as a way to both treat and protect against disease.
Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? - 2014 - http://www.ncbi.nlm.nih.gov/pubmed/24977967
Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? - 2004 - http://www.ncbi.nlm.nih.gov/pubmed/15159679 - Russo - Republished in 2008 - http://www.ncbi.nlm.nih.gov/pubmed/18404144
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects- 2011 - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165946/ - This review, written by Ethan Russo MD, and published in the British Journal of Pharmacology, explores another echelon of phytotherapeutic agents, the cannabis terpenoids: limonene, myrcene, a-pinene, linalool, b-caryophyllene, caryophyllene oxide, nerolidol and phytol. These chemicals, which give cannabis its unique aroma, have therapeutic qualities all unto themselves.
The Human Endocannabinoid System & Clinical Endocannabinoid Deficiency - https://www.youtube.com/watch?v=03RfMtv1jQs